- Home
- ABUS vs CRSR Comparison
ABUS vs CRSR Comparison
Compare ABUS & CRSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- CRSR
- Stock Information
- Founded
- ABUS 2005
- CRSR 1994
- Country
- ABUS United States
- CRSR United States
- Employees
- ABUS N/A
- CRSR N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- CRSR Computer Manufacturing
- Sector
- ABUS Health Care
- CRSR Technology
- Exchange
- ABUS Nasdaq
- CRSR Nasdaq
- Market Cap
- ABUS 685.7M
- CRSR 958.7M
- IPO Year
- ABUS N/A
- CRSR 2020
- Fundamental
- Price
- ABUS $3.22
- CRSR $9.44
- Analyst Decision
- ABUS Strong Buy
- CRSR Buy
- Analyst Count
- ABUS 4
- CRSR 6
- Target Price
- ABUS $5.50
- CRSR $10.00
- AVG Volume (30 Days)
- ABUS 801.2K
- CRSR 539.7K
- Earning Date
- ABUS 07-31-2025
- CRSR 07-31-2025
- Dividend Yield
- ABUS N/A
- CRSR N/A
- EPS Growth
- ABUS N/A
- CRSR N/A
- EPS
- ABUS N/A
- CRSR N/A
- Revenue
- ABUS $6,403,000.00
- CRSR $1,348,872,000.00
- Revenue This Year
- ABUS $3.35
- CRSR $14.40
- Revenue Next Year
- ABUS N/A
- CRSR $9.76
- P/E Ratio
- ABUS N/A
- CRSR N/A
- Revenue Growth
- ABUS N/A
- CRSR N/A
- 52 Week Low
- ABUS $2.71
- CRSR $5.60
- 52 Week High
- ABUS $4.73
- CRSR $13.02
- Technical
- Relative Strength Index (RSI)
- ABUS 32.83
- CRSR 55.90
- Support Level
- ABUS $3.04
- CRSR $8.80
- Resistance Level
- ABUS $3.65
- CRSR $9.68
- Average True Range (ATR)
- ABUS 0.13
- CRSR 0.31
- MACD
- ABUS -0.05
- CRSR -0.04
- Stochastic Oscillator
- ABUS 8.20
- CRSR 52.66
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About CRSR Corsair Gaming Inc.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.